Breaking News

Janssen Forms New Group

By Kristin Brooks | January 22, 2014

Will target new medicines to address unmet health needs

Janssen, the pharmaceutical companies of Johnson & Johnson, has formed Janssen Global Public Health (Janssen GPH), a new group aimed at unifying Janssen's R&D to deliver new medicines to address unmet public health needs. Janssen GPH will partner with other organizations within the company to advance its global public health goals. 

Adrian Thomas, M.D., vice president of Global Market Access, Global Commercial Strategy Operations, and Global Public Health, and Wim Parys, M.D., vice president, R&D Global Public Health, will jointly lead Janssen GPH. Janssen GPH will be responsible for clinical and product development and creating and implementing new strategies for its portfolio of pharmaceuticals, diagnostics, and services for diseases impacting resource-limited countries and emerging markets.
The products include: SIRTURO, approved by the FDA as a combination therapy in adults with pulmonary multi-drug resistant tuberculosis (MDR-TB); long-acting rilpivirine, an injectable version of the HIV medicine; Dapivirine microbicidal ring, an investigational HIV medicine for use as a monthly vaginal microbicidal ring to prevent sexual transmission of HIV; reformulated flubendazole, a potential new treatment against parasites that cause elephantiasis and river blindness; and reformulated mebendazole, a chewable formulation of VERMOX to treat intestinal worms in young children.
Additionally, Janssen GPH will work on the UNITE Project, a consortium between Janssen and several partners with expertise in HIV/AIDS, working to improve health outcomes for people living with HIV via the use of mobile technologies (mHealth).
"We are applying our expertise where we can make the biggest impact," said Dr. Thomas. "Our goal is to address seemingly intractable health challenges in new and unexpected ways."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.